The UN Commission on Life-Saving Commodities for Women and Children

The Maternal Health Technical Resource Team

Transition to Maternal Health Caucus

RHSC Annual Meeting, October 2016
Availability of Quality Maternal Health Products [AQMHP]

- 4 products were pre-qualified, 1 ERP, 3 submitted for PQ, 3 receiving support
  - **Misoprostol** – 2 products PQed (Cipla/India & Acme/India); 1 ERP approved (China Resources Zizhu Pharm./China), 2 receiving support
  - **Oxytocin** - 1 product PQed (Grindeks/Latvia), 1 submitted for PQ, 1 receiving support
  - **Magnesium Sulfate**: 1 product PQed (Inresa Arzneimittel GmbH/Germany), 2 products submitted for PQ
Key Achievements Phase I and II

- File submitted and accepted to modify WHO EML of MgSO4
  - "For injection: 0.5g/ mL in 2 mL ampoule; 0.5g/ mL in 10 mL ampoule (50% w/v)

- Storage conditions for oxytocin: a brief overview document

- Quality Procurement workshop successfully held in Kampala (9/2015) & Tunis (7/2016)
  - Uganda, Kenya, Tanzania, Malawi, Zambia and Zimbabwe attended Kampala workshop. Tunisia, Niger, Congo, Cameroon, Benin, Burkina Faso and Senegal attended Tunis workshop. Both workshops included procurement decision makers, regulators & MOH program staff.
  - Quantification and other tools were disseminated

- Collaborated with the GRAMPS TRT (quality, regulatory and procurement tools)
Key Achievements Phase I and II

Essential Medicines List

- Inclusion of life-saving commodities (misoprostol) in national EMLs: DRC, Sierra Leone
- Development of EML Search, a searchable database of national EMLs
- Advocacy resource guide developed with information on the process of updating and revising national EMLs: Updating National EMLs: A Step-by-Step Advocacy Guide
- Information packages on each commodity in final stages of development
Key Achievements Phase I and II

**Oxytocin in the Cold Chain**

- Facilitated development and dissemination of UNICEF/WHO Joint statement: Temperature Sensitive Health Products in the EPI Cold Chain
- Options Analysis and case studies completed in Ghana and Mali for inclusion of oxytocin in cold chain
- Ghana govt has committed to putting oxytocin in the cold chain. Mali in process but stalled
- Brief developed with guidance on how to integrate oxytocin in cold chain
Key Achievements Phase I and II

Commodity Security

- MH Commodity Security (MHCS) Framework and White Paper developed
- Validation exercises with multiple relevant stakeholders conducted in 3 countries (Tanzania, Ethiopia, and Nigeria)
- MHCS brief developed, incorporating country feedback
- Developed webinar materials (slide deck and script) applying the MHCS framework to a fictional country case study and conducted webinar
- Translated webinar materials into Spanish and French to be adapted for use
Key Achievements Phase I and II

Innovation

- 3 pill pack of misoprostol produced by manufacturer
- Research on rectal MgSO4 conducted and determined non-viable option
- Study on use of Temperature Time Indicator (TTI) on oxytocin in Ghana completed by 10/2016
Key Achievements Phase I and II

Guideline development and dissemination

- Developed a protocol, applied and adapted in 3 countries (Ethiopia, Tanzania and Uganda)
  - Identified strategies with stakeholders to overcome barriers to implement guidelines
  - Prioritized feasible implementation strategies
  - Technical and logistical support provided by WHO and GREAT Network to facilitate guidelines implementation at the country level
Key Achievements Phase I and II

**Guideline development and dissemination**

- Provided continuous support to strengthen local research capacity in the science and practice of knowledge translation (KT) and implementation research (IR) – through GREAT Network seed grants
- Developed and offered online Practicing Knowledge Translation (PKT) course to in-country partners in collaboration with experts in KT and IR
Dissemination Activities

• **Uganda and Tunis Quality Procurement Workshop** was an opportunity to disseminate various tools and resources of the MHTRT, including quantification guidance.

• Presented **MHTRT panels** at **GMNH conference in Mexico City and RHSC annual membership meeting**.

• **Flash drives with tools and resources from multiple TRTs** distributed during workshop, conference and meeting.

• **Tools and resources** uploaded on lifesavingcommodities.org and partners’ websites.

• Newly prequalified products (Cipla’s misoprostol and Grindeks’ oxytocin) were announced through the RHSC platform.